Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Division of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany.
Nat Rev Cancer. 2020 Nov;20(11):681-694. doi: 10.1038/s41568-020-00300-6. Epub 2020 Oct 6.
Metastatic dissemination occurs very early in the malignant progression of a cancer but the clinical manifestation of metastases often takes years. In recent decades, 5-year survival of patients with many solid cancers has increased due to earlier detection, local disease control and adjuvant therapies. As a consequence, we are confronted with an increase in late relapses as more antiproliferative cancer therapies prolong disease courses, raising questions about how cancer cells survive, evolve or stop growing and finally expand during periods of clinical latency. I argue here that the understanding of early metastasis formation, particularly of the currently invisible phase of metastatic colonization, will be essential for the next stage in adjuvant therapy development that reliably prevents metachronous metastasis.
转移扩散在癌症的恶性进展中很早就发生了,但转移的临床表现通常需要数年时间。近几十年来,由于早期发现、局部疾病控制和辅助治疗,许多实体癌患者的 5 年生存率有所提高。因此,随着更多的抗增殖癌症治疗延长了疾病进程,我们面临着晚期复发的增加,这引发了关于癌细胞在临床潜伏期如何存活、进化或停止生长并最终扩张的问题。我在这里认为,对早期转移形成的理解,特别是对目前不可见的转移定植阶段的理解,对于发展可靠地预防异时性转移的辅助治疗的下一阶段至关重要。